Prabhani Atukorale

The Atukorale Lab engineers immunomodulatory nanoparticles to reprogram the tumor immune microenvironment in difficult-to-treat and metastatic cancers. Nanoparticle platforms are designed to co-deliver synergistic innate immune agonists and to support novel cancer vaccination strategies. The lab also works to improve the clinical performance of checkpoint inhibitors and CAR T cell therapies through combination with these engineered nanomaterials.